期刊名称：JOURNAL OF DUAL DIAGNOSIS
|
ISSN： | 1550-4263
|
|
出版频率： | Quarterly
|
|
出版社： | ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD, 2-4 PARK SQUARE, MILTON PARK, ABINGDON, ENGLAND, OXON, OX14 4RN
|
|
出版社网址： | http://www.tandfonline.com/
|
|
期刊网址： | http://www.tandfonline.com/toc/wjdd20/current#.UrEPFWzxuM8
|
|
影响因子： |
0.839(2015年)
1.044(2014年)
0.815(2013年)
0.730 (2012年)
|
| 主题范畴： | PSYCHOLOGY, CLINICAL; SUBSTANCE ABUSE; PSYCHIATRY |
| 变更情况： | Journal of Chemical Dependency Treatment (1987 - 2006) ;Journal of Dual Diagnosis (1900 - current) |
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Journal of Dual Diagnosis is a quarterly, international publication that focuses on the full spectrum of complexities regarding dual diagnosis. The co-occurrence of mental health and substance use disorders, or “dual diagnosis,” is one of the quintessential issues in behavioral health. Why do such high rates of co-occurrence exist? What does it tell us about risk profiles? How do these linked disorders affect people, their families, and the communities in which they live? What are the natural paths to recovery? What specific treatments are most helpful and how can new ones be developed? How can we enhance the implementation of evidence-based practices at clinical, administrative, and policy levels? How can we help clients to learn active recovery skills and adopt needed supports, clinicians to master new interventions, programs to implement effective services, and communities to foster healthy adjustment? The Journal addresses each of these perplexing challenges.
Journal of Dual Diagnosis includes articles and perspectives from four overarching domains relevant to the field: Psychopharmacology & Neurobiology; Psychotherapy & Psychosocial Issues; Services & Policy; and Clinical Forum. Each issue serves to encourage integration of these domains. The Journal seeks to publish articles relevant to a wide range of people interested in dual diagnosis: researchers, physicians, clinicians, trainees, administrators, and policy makers. High-quality empirical research, brief reports, timely reviews, thought-provoking commentaries, and ongoing discussions of clinical issues will be considered for publication, all with the aim of developing a better understanding of the basis of, and optimal treatment for, co-occurring psychiatric and substance use disorders.
The Journal of Dual Diagnosis is abstracted/indexed in: PsycINFO
Subjects covered by this journal
Instructions to Authors
Journal of Dual Diagnosis is a quarterly, international publication that focuses on the full spectrum of complexities regarding dual diagnosis. The co-occurrence of mental health and substance use disorders, or “dual diagnosis,” is one of the quintessential issues in behavioral health. Why do such high rates of co-occurrence exist? What does it tell us about risk profiles? How do these linked disorders affect people, their families, and the communities in which they live? What are the natural paths to recovery? What specific treatments are most helpful and how can new ones be developed? How can we enhance the implementation of evidence-based practices at clinical, administrative, and policy levels? How can we help clients to learn active recovery skills and adopt needed supports, clinicians to master new interventions, programs to implement effective services, and communities to foster healthy adjustment? The Journal addresses each of these perplexing challenges.
Journal of Dual Diagnosis includes articles and perspectives from four overarching domains relevant to the field: Psychopharmacology & Neurobiology; Psychotherapy & Psychosocial Issues; Services & Policy; and Clinical Forum. Each issue serves to encourage integration of these domains. The Journal seeks to publish articles relevant to a wide range of people interested in dual diagnosis: researchers, physicians, clinicians, trainees, administrators, and policy makers. High-quality empirical research, brief reports, timely reviews, thought-provoking commentaries, and ongoing discussions of clinical issues will be considered for publication, all with the aim of developing a better understanding of the basis of, and optimal treatment for, co-occurring psychiatric and substance use disorders.
Please note that Journal of Dual Diagnosis uses CrossCheck™ software to screen papers for unoriginal material. By submitting your paper to Journal of Dual Diagnosis you are agreeing to any necessary originality checks your paper may have to undergo during the peer review and production processes. POLICIES
The policies of the Journal of Dual Diagnosis are in accordance with the International Committee of Medical Journal Editors.
Previous Publication
By submitting a manuscript, authors are declaring that neither the manuscript nor its data have been previously published (except in abstract) or are currently under consideration for publication.
Authorship
All persons designated as authors should qualify for authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. The corresponding author affirms that he or she had access to all data from the study, both what is reported and what is unreported, and also that he or she had complete freedom to direct its analysis and its reporting, without influence from the sponsors. The corresponding author also affirms that there was no editorial direction or censorship from the sponsors. Preparation of drafts of manuscripts by employees of the sponsor who are not listed as authors is expressly prohibited.
Authorship credit should be based on:
- Substantial contributions to conception and design or analysis and interpretation of data.
- Substantial contributions to drafting the article or revising it critically for important intellectual content.
- Final approval of the version to be published
- Participation was not limited only to the acquisition of funding for the research or position as chair or director of a relevant department, division, or research group.
All four conditions must be met. Participation solely in the acquisition of funding or the collection of data does not justify authorship. General supervision of the research group is also not sufficient. Any part of an article critical to its main conclusions must be the responsibility of at least one author. Only those with key responsibility for the material in the article should be listed as authors; all others contributing to the work should be recognized in the Acknowledgments section.
Disclosure of Potential Conflicts of Interest
The submission must contain an explicit and unambiguous statement describing any potential conflict of interest, or lack thereof, for all of the authors as it relates to the subject of the article. Examples include: “Dr. Smith reports no financial relationships with commercial interests.” “Dr. Smith receives compensation as a consultant for XYZ Company, a manufacturer of antidepressants.” “Dr. Jones and Dr. Smith have financial holdings in ABC Company, which distributes haloperidol.” “Dr. Jones owns a patent on the diagnostic device described in this article.” These statements acknowledging or denying conflicts of interest must be included in the manuscript under the heading “Disclosures,” which should appear just before “References.”
There must also be a listing for each author, detailing the names of organizations, institutions, companies, and individuals from whom they have received compensation for professional services in any of the previous three years, or from whom they anticipate receiving such compensation in the near future, whether or not these affiliations appear to have any relevance to the topic covered in the submission. Neither the precise amount received from each entity nor the aggregate income from these sources needs to be provided. Professional services include any activities for which the individual is, has been, or will be compensated with cash, royalties, fees, stock or stock options in exchange for work performed, advice or counsel provided, or for other services related to the author’s professional knowledge and skills. This would include, but not necessarily be limited to, the identification of organizations from which the author received contracts or in which he or she holds an equity stake if professional services were provided in conjunction with the transaction. The authors are expected to disclose any other financial holdings or considerations, such as stocks, bonds or donations of supplies or equipment that a reasonable person could construe as possibly influencing the objectivity of the report.
The Journal of Dual Diagnosis will not make specific recommendations as to whether a relationship requires disclosing. If there is a question as to whether a relationship is relevant, disclosure is the preferred course of action.
The Editors will review all author statements of financial support to determine if there is evidence of bias from these sources. If it appears that there may be a bias, then further review and possible rejection of the manuscript may occur. Authors are encouraged to contact the Editor at any stage in the manuscript review process if they believe that they have relationships that require review.
Protection of Human Subjects and Animals in Research
Manuscripts that describe research with human subjects or animals must explicitly state that the research was conducted in accord with relevant legal and ethical standards. Authors must state the name of the committee (e.g., IRB) that approved and monitored the study. For research with human subjects, authors must include statements indicating that there was a complete discussion of the study with potential participants; that written informed consent was obtained after this discussion (or if a waiver of consent was obtained, an explanation of this); and that the study was conducted in accordance with the Declaration of Helsinki. For research conducted with animals, authors must indicate that institutional and national guidelines for the care and use of animals were followed.
Confidentiality
Participants and patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance, and editors should so note that such alterations do not distort scientific meaning.
Registration of Clinical Trials
Broad access to the research literature and the rights of our authors are important to the Journal of Dual Diagnosis . The journal requires, as a condition of consideration for publication, registration of clinical trials in an acceptable public trials registry. Trials must be registered at or before the onset of patient enrollment. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like. The Journal does not advocate one particular registry, but requires authors to register their trial in a registry that meets several criteria. The registry must be accessible to the public at no charge. It must be open to all prospective registrants and managed by a not-for-profit organization. There must be a mechanism to ensure the validity of the registration data, and the registry should be electronically searchable. Authors are required to report which registry they use and the number of their study within that registry.
MANUSCRIPT PREPARATION AND SUBMISSION
The Journal of Dual Diagnosis receives all manuscript submissions electronically via its ScholarOne Manuscripts site located at: http://mc.manuscriptcentral.com/wjdd . ScholarOne Manuscripts allows for rapid submission of original and revised manuscripts, and facilitates the review process and internal communication between authors, editors, and reviewers via a web-based platform. ScholarOne technical support can be accessed at http://scholarone.com/services/support/ . If you have any other requests, please contact the journal’s managing editor, Stephanie Acquilano, at Stephanie.c.acquilano@dartmouth.edu .
General
Manuscripts should be prepared in accordance with the Publication Manual of the American Psychological Association , Sixth Edition. The manuscript (except tables and figures) must be formatted with one-inch margins all around, double-spaced, and font Times New Roman 12. All pages must be numbered. Use jargon and abbreviations sparingly. Use active voice, first person, and short sentences whenever possible. Language should be gender-neutral and follow the people-first philosophy.
Please consult our guidance on keywords here . Authors are responsible for obtaining permission to reproduce copyrighted material from other sources and are required to sign an agreement for the transfer of copyright to the publisher. As an author, you are required to secure permission if you want to reproduce any figure, table, or extract from the text of another source. This applies to direct reproduction as well as "derivative reproduction" (where you have created a new figure or table which derives substantially from a copyrighted source). All accepted manuscripts, artwork, and photographs become the property of the publisher.
Types of Submissions
The Journal of Dual Diagnosis will accept a range of manuscripts for consideration. These are described below. All word limitations refer only to the “Text” section of the manuscript (i.e., Introduction, Methods, Results, and Discussion).
Articles (research and non-research reports)
Articles should not exceed 3,500 words, although some exceptions may be granted by the Editors. Generally, articles will be research reports of original work, presenting new data based on a relative large number of participants. Appropriate research will follow the highest scientific standards and offer important advances in the field of co-occurring disorders.
Brief Reports
Brief Reports should not exceed 2,000 words. These manuscripts are typically reports of research based on a relatively small number of participants, or of research yielding important information for the field of co-occurring disorders despite substantial limitations.
Literature Reviews
Reviews will typically be invited by the Editors, but the Journal will accept unsolicited manuscripts. Reviews should not exceed 7,000 words in length, should focus on recent literature, and should synthesize important information on a topic of special interest to the field of co-occurring disorders.
Editorials & Commentaries
While editorials and commentaries will typically be invited by the Editors, the Journal will accept uninvited submissions of less than 2,000 words.
Clinical Reviews
Clinical reviews will be included in the “Clinical Forum” section of the Journal. These manuscripts should present high-quality literature reviews on a topic of substantial importance in the clinical care of people with co-occurring disorders, along with a case description that illustrates the major features of the topic. Both invited and uninvited manuscripts that conform to this format will be accepted for review. Manuscripts submitted for the Clinical Forum section should not exceed 3,500 words, and should lead with the case description followed by the literature review.
Letters to the Editors
Letters should not exceed 500 words and will be published at the discretion of the Editors. Case reports that are not supported by a literature review and synthesis may be submitted as a letter.
Format of Submissions
Submissions to the Journal must include three parts: (1) cover memo, (2) manuscript (with tables and figures included at the end of the document), and (3) signed author forms from all authors. Specific instructions for each are below.
1. Cover Memo
This can be a separate memo or part of the email that accompanies the manuscript.
· State that neither the manuscript nor its data have been previously published (except in abstract) or are currently under consideration for publication;
· Acknowledge that the manuscript will become the property of the Journal while under review and when or if the manuscript is accepted for publication;
· Include what type of manuscript is being submitted; and
· Provide the names and email addresses of three experts as possible reviewers for the manuscript.
2. Manuscript
Title Page
Title: Succinct and descriptive
Short Title: Maximum of 50 characters and spaces
Authors:
· Full names
· Highest degree
· Academic or professional affiliations
· E-mail addresses
Corresponding Author:
· Complete mailing address
· telephone & fax numbers
· E-mail address
Abstract Page
Abstract:
· Structured under the headings of Objective ; Methods (for review articles it will be important to specify the methods of literature search and selection); Results ; and Conclusions .
· Reports of clinical trials should include the essential information identified in the CONSORT guidelines for abstracts [SCA2] .
· If applicable, clinical trial registration information (registry name and trial number) should be listed at the end of the abstract. This will not count against the word limit.
· See the table for word limits and instances where a structured abstract is not required.
Keywords: The abstract should be followed by a list of 3–10 keywords.
Text
The main body of the manuscript must be structured into the sections listed below. Non-research articles do not have to follow this format.
Introduction
Methods , including statements indicating:
· There was a complete discussion of the study with potential participants;
· Written informed consent was obtained after this discussion (or if a waiver of consent was obtained, an explanation of this); and
· The study was conducted in accordance with the Declaration of Helsinki, including the name of the committee (e.g., IRB) who approved and monitored the study.
Results
Discussion , including a description of the strengths and limitations of the study.
Acknowledgments
· Recognize people who contributed in an important way to the manuscript.
· List ALL financial support received for the study.
· For grants, include the grant number and the full name of the granting agency.
· If the paper was presented at a meeting in the last three years, give the meeting name, city and state, and full meeting dates.
Disclosures
· Include statements for all authors regarding any conflict of interest (or lack thereof) as it relates to the subject of this manuscript. Examples of such statements include:
“Dr. Smith reports no financial relationships with commercial interests.”
“Dr. Smith receives compensation as a consultant for XYZ Company, a manufacturer of antidepressants.”
“Dr. Jones and Dr. Smith have financial holdings in ABC Company, which distributes haloperidol.”
“Dr. Jones owns a patent on the diagnostic device described in this article.”
· Include a listing for each author, detailing the names of organizations, institutions, companies, and individuals, including intermediaries such as sub-contractors or conference organizers, from whom they have received compensation for professional services in any of the previous three years, or from whom they anticipate receiving such compensation in the near future, whether or not these affiliations appear to have any relevance to the topic covered in the submission. Neither the precise amount received from each entity nor the aggregate income from these sources needs to be provided. Professional services include any activities for which the individual is, has been, or will be compensated with cash, royalties, fees, stock or stock options in exchange for work performed, advice or counsel provided, or for other services related to the author’s professional knowledge and skills. This would include, but not necessarily be limited to, the identification of organizations from which the author received contracts or in which he or she holds an equity stake if professional services were provided in conjunction with the transaction. The authors are expected to disclose any other financial holdings or considerations, such as stocks, bonds or donations of supplies or equipment that a reasonable person could construe as possibly influencing the objectivity of the report.
References
· References should be timely and highlight the study’s relevance.
· When available, doi’s must be included at the end of each reference.
· Only material that has been published, accepted for publication, or presented at a major national meeting should be included in the reference list. If unpublished material is cited, note the source and year in parentheses in the text of the paper. Citation of unpublished material should be kept to a minimum.
· References should be prepared in accordance with the Publication Manual of the American Psychological Association , Sixth Edition. Cite in the text by author and date (Smith, 1983) and include an alphabetical list at the end of the article. Examples:
Journal
Tsai, M., & Wagner, N. N. (1978). Therapy groups for women sexually molested as children. Archives of Sexual Behaviour, 7 (6), 417–427. doi: 10.1007/BF01542487
Book
Millman, M. (1980). Such a pretty face . New York, NY: W. W. Norton.
Contribution to a Book
Hartley, J. T., & Walsh, D. A. (1980). Contemporary issues in adult development of learning. In L. W. Poon (Ed.), Ageing in the 1980s (pp. 239–252). Washington, DC: American Psychological Association.
Tables and Figures
Tables and figures should not be embedded in the text, but should be included at the end of the manuscript, each on a separate page. They must:
· Be formatted as editable files.
· Follow guidelines in the Publication Manual of the American Psychological Association , Sixth Edition.
· Include a short descriptive title, with a clear legend and any footnotes suitably identified below. All units must be included.
· Be completely labeled, taking into account necessary size reduction.
· Be mentioned specifically in the text of the manuscript.
· Be no smaller than font size 10.
Illustrations
Illustrations submitted (line drawings, halftones, photos, photomicrographs, etc.) should be clean originals or digital files. Digital files are recommended for highest quality reproduction and should follow these guidelines:
• 300 dpi or higher
• Sized to fit on journal page
• EPS, TIFF, or PSD format only
• Submitted as separate files, not embedded in text files
Color Illustrations
Color art will be reproduced in color in the online publication at no additional cost to the author. Color illustrations will also be considered for print publication; however, the author will be required to bear the full cost involved in color art reproduction. Please note that color reprints can only be ordered if print reproduction costs are paid. Print Rates: $900 for the first page of color; $450 per page for the next three pages of color. A custom quote will be provided for articles with more than four pages of color. Art not supplied at a minimum of 300 dpi will not be considered for print.
|
Type of Manuscript |
Word Limit |
Abstract |
Organized in four sections of Introduction, Methods, Results, and Discussion |
|
Article
-Research
-Non Clinical Trial |
3,500 |
Yes
Structured
350 words |
Yes |
|
Article
-Research
-Clinical Trial |
3,500 |
Yes
Structured
CONSORT
350 words |
Yes |
|
Article
-Non Research |
3,500 |
Yes
Unstructured
350 words |
No
Organize logically according to topic |
|
Brief Report |
2,000 |
Yes
Structured
200 words |
Yes |
|
Literature Review |
7,000 |
Yes
Structured
350 words |
Yes
Methods refers to method of searching the literature and selecting articles for review |
|
Editorial / Commentary |
2,000 |
No |
No
Organize logically according to topic |
|
Clinical Review |
3,500 |
Yes
Unstructured
350 words |
No
Organize logically according to topic |
|
Letter to Editors |
500 |
No |
No |
3. Author Forms
In accord with the Journal’s policies outlined earlier, all authors must complete and sign an Author Form . These forms must be included at the time of manuscript submission.
REVIEW OF MANUSCRIPTS
Manuscripts submitted for publication, including invited papers, will receive initial review by one of the Editors or Associate Editors to evaluate the originality, validity, importance of content and conclusions, and the appropriateness of the topic for the Journal. Manuscripts with insufficient priority for publication will be rejected immediately. This rapid rejection process enables the author to promptly submit for publication elsewhere. Otherwise, manuscripts will be sent for unblinded review by two to three independent peer reviewers. A separate statistical or other specialized review is obtained whenever an Editor or Associate Editor deems it appropriate. All reviewers remain anonymous. Authors will usually be notified of a decision within three months, although some delays may be unavoidable.
ACCEPTED MANUSCRIPTS ONLINE
Manuscripts that have been accepted will promptly become available online, in their pre-publication form. The accepted papers will be available in a section on the Journal’s page entitled “Forthcoming Articles.” Posted papers will be clearly labeled as the “Accepted, uncorrected manuscript” versions and will include DOI numbers so that the papers can be cited and referenced. Authors will also receive notification from Taylor & Francis Online when their raw manuscript is posted and once again when the final version is posted. The papers in this section will be removed once the final typeset version is posted online.
PROOFS
Page proofs are sent to the designated author using Taylor & Francis’ Central Article Tracking System (CATS). They must be carefully checked and returned within 48 hours of receipt.
REPRINTS AND COMPLIMENTARY POLICY
Reprints of individual articles are available for order at the time that authors review page proofs. A discount on reprints is available to authors who order before print publication. Each corresponding author will receive three complete issues in which the article was published and a PDF file of the article via e-mail. This file is for personal use only and may not be copied or disseminated in any form without prior written permission from Taylor & Francis Group, LLC. Authors for whom we receive a valid e-mail address will be provided an opportunity to purchase reprints of individual articles, or copies of the complete print issue. These authors will also be given complimentary access to their final article on Taylor & Francis Online .
OPEN ACCESS
Taylor & Francis Open Select provides authors or their research sponsors and funders with the option of paying a publishing fee and thereby making an article fully and permanently available for free online access – open access – immediately on publication to anyone, anywhere, at any time. This option is made available once an article has been accepted in peer review. Full details of our Open Access program .
Editorial Board
EDITORS
Alan I. Green, MD
Raymond Sobel Professor of Psychiatry
Professor of Pharmacology and Toxicology
Chairman, Department of Psychiatry
Geisel School of Medicine at Dartmouth
Robert E. Drake, MD, PhD
Andrew Thomson Professor of Psychiatry
Professor of Community & Family Medicine
Geisel School of Medicine at Dartmouth
ASSOCIATE EDITORS
Melanie E. Bennett, PhD
Associate Professor of Psychiatry, University of Maryland School of Medicine, MD
Acting Director of Education, VA Capital Network (VISN 5) Mental Illness Research, Education and Clinical Center (MIRECC)
Mary F. Brunette, MD
Associate Professor of Psychiatry
Geisel School of Medicine at Dartmouth
Kim T. Mueser, PhD
Executive Director
Center for Psychiatric Rehabilitation
Professor of Occupational Therapy
Boston University
Douglas L. Noordsy, MD Associate Professor of Psychiatry
Geisel School of Medicine at Dartmouth
Rob Whitley, PhD
Assistant Professor of Psychiatry, McGill University, Montreal, Canada
Assistant Professor of Psychiatry, The Geisel School of Medicine at Dartmouth, Lebanon, NH
MANAGING EDITOR
Stephanie C. Acquilano, MA
Research Associate, Department of Psychiatry
Geisel School of Medicine at Dartmouth
EDITORIAL BOARD
Caleb Adler, MD - Associate Professor
Psychiatry and Neuroscience, University of Cincinnati, Cincinnati, OH
Christine Barrowclough, PhD - Professor
Clinical Psychology, University of Manchester , Manchester, United Kingdom
Gary Bond, PhD - Professor
Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH
E. Sherwood Brown, MD, PhD - Professor
Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX
R. Andrew Chambers, MD - Associate Professor
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN
Patricia E. Deegan, PhD - Independent Consultant
Pat Deegan, PhD & Associates, LLC, Byfield, MA
Deepak Cyril D'Souza, MD - Associate Professor
Department of Psychiatry, Yale University School of Medicine , New Haven, CT, and Director, Schizophrenia Research Program, VA Connecticut HealthCare System, West Haven, CT
A. Eden Evins, MD, MPH - Associate Professor
Department of Psychiatry, Harvard Medical School , and Director, Center for Addiction Medicine, Massachusetts General Hospital, Boston, MA
Lindy Fox Smith, MA, LADC - Mental Health and Substance Abuse Use Trainer/Consultant
LB FOX & Associates, LLC, Panama City Beach, FL
Christine E. Grella, PhD - Professor
Department of Psychiatry & Biobehavioral Sciences, UCLA Integrated Substance Abuse Programs, Los Angeles, CA
Andreas Heinz, MD - Director and Chair
Department of Psychiatry, Charité - University Medical Center, Berlin, Germany
Elie Karam MD - Professor & Head
Department of Psychiatry & Clinical Psychology, St. George Hospital University Medical Center, Beirut, Lebanon
David Kavanagh, PhD - Professor
School of Psychology & Counselling and Institute of Health & Biomedical Innovation Queensland University of Technology, Brisbane, Australia
Ronald C. Kessler, PhD - Professor
Department of Health Care Policy, Harvard Medical School, Boston, MA
Mark P. McGovern, PhD - Professor
Department of Psychiatry and of Community & Family Medicine, Dartmouth Medical School, Lebanon, NH
Ingrid Melle, MD, PhD - Professor
Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, Oslo Norway
Vicki A. Nejtek, PhD - Associate Professor
Department of Psychiatry and Behavioral Health
Director of Co-Occurring Disorders Research, University of North Texas Health Science Center, Fort Worth, TX
Roger H. Peters, PhD - Professor
Department of Mental Health Law and Policy, Louis de la Parte Florida Mental Health Institute, University of South Florida, Tampa, FL
Stéphane Potvin, PhD
Fernand-Seguin Research Center of Hôpital Louis-H. Lafontaine, Department of Psychiatry, Faculty of Medicine, University of Montréal, Montréal, Québec, Canada
Trevor W. Robbins, FRS, FMed Sci - Professor
Department of Cognitive Neuroscience and Experimental Psychology (Head of Department)
Director, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge United Kingdom
Robert A. Rosenheck, MD - Professor
Department of Psychiatry, Public Health and the Child Study Center, Yale University School of Medicine, New Haven, CT
David A. Smelson, PsyD - Professor and Vice Chair
Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA
Roger D. Weiss, MD - Professor
Department of Psychiatry, Harvard Medical School, Boston, MA and Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA
Haiyi Xie, PhD - Associate Professor
Department of Community & Family Medicine, Dartmouth Medical School, Lebanon, NH
Douglas M. Ziedonis, MD, MPH - Professor and Chairman
Department of Psychiatry, University of Massachusetts Medical School/UMass Memorial Health Care, Worcester, MA
| 
